The FDA Authorized Test for TFR Initiation and Monitoring

The MRDx® BCR-ABL Test is a companion diagnostic for Chronic Myeloid Leukemia (CML) patients in the chronic phase (CP) being treated with Tasigna®* who may be candidates for treatment discontinuation and monitoring of treatment-free remission (TFR). Read our Press Release.

Monitoring of TFR requires the ability to accurately measure BCR-ABL transcripts to a depth, classified as MR4.5 (BCR-ABL/ABL ≤0.0032% International Scale).

The MRDx BCR-ABL Test has consistently demonstrated sensitivity in ENESTfreedom and ENESTop clinical studies to MR4.5. The MRDx BCR-ABL Test is based on real-time quantitative PCR and measures BCR-ABL transcripts (e13a2/b2a2 and/or e14a2/b3a2) from peripheral blood specimens in CML-CP Ph+ patients.

MRDx® BCR-ABL Test Brochure


The MRDx BCR-ABL Kit as well as Test can be ordered directly through MolecularMD. Additional reference laboratories will offer the test once it gets established within their systems.

Physician Test Report for MRDx Test Results (sample)

MRDx BCR-ABL Test Requisition Form

Specimen Preparation and Shipping Instructions


Contact Us

Phone: 1-866-GET-MRDX (438-6739)



*Tasigna is a registered trademark of Novartis AG